VERTEX PHARMACEUTIC (VX1.SG)


Stuttgart - Stuttgart Delayed Price. Currency in EUR
88.78-0.28 (-0.32%)
As of 2:06 AM EDT. Market open.
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open88.78
Prev Close89.06
Bid88.83 x 50000
Ask89.76 x 100000
Day's Range88.78 - 88.78
52wk Range67.08 - 126.50
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
Volume0
Avg Vol (3m)66
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • Vertex (VRTX) To Stop VX-661-Ivacaftor Study, Stock Down
    Zacks8 days ago

    Vertex (VRTX) To Stop VX-661-Ivacaftor Study, Stock Down

    Vertex's (VRTX) shares were down in pre-market trading on the company's announcement that it will be stopping one of the phase III studies on its VX-661-ivacaftor combination.

  • CNBC8 days ago

    After-hours buzz: HAIN, FN, VRTX & more

    Check out the companies making headlines after the bell on Monday.

  • Barrons.com15 days ago

    Biotech Stocks: Blame Gilead?

    Now that biotech companies like Alexion Pharmaceuticals (ALXN), Vertex Pharmaceuticals (VRTX), and Amgen (AMGN) have finished reporting earnings, Leerink's Geoffrey Porges look at the accuracy of his predictions and find that most of them were pretty good. Gilead reported revenues were 5% below our forecast, vs consensus, which was 1% greater, and earnings were 7% below our estimate (vs. 2% above consensus).